- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00407836
Efficacy Study of T Cell Vaccination in HIV Infection
December 1, 2009 updated by: Soroka University Medical Center
Phase II Study of Efficacy, Tolerability and Safety of CD4-Specific T-cell Vaccine in HIV Infection
The hallmark of HIV infection and AIDS is the continuous attrition of CD4 T cells.
One of the mechanisms that may account for the CD4 attrition , is autoimmunity against the CD4 T cells, caused by autologous immune cells.
Vaccination against autoimmune reactive T cells has been successfully tried in animal models of autoimmune diseases and is now being tried in patients with Multiple Sclerosis.
The purpose of the present study is to test this hypothesis in HIV infection.
We will vaccinate HIV infected patients in whom specific autoimmune reactivity against CD4 is present , with their own CD4 reactive T cells.
Following that, we shall study the patients and find out if the T cell vaccination caused a rise in CD4 T cell levels, and whether it influenced HIV viral load, as well as HIV and CD4 specific immunity.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The study will be based on forty HIV infected patients, receiving anti retroviral treatment (HAART), with CD4 levels between 150-350 and HIV plasma viral load < 5000, for at least 12 months and despite continuous anti-retroviral treatment.
The patients will be randomly divided into two groups, one that will get the T cell vaccination, and the other that will serve as controls.
The T cell vaccine will be prepared from autologous T cells that responded by specific proliferation to recombinant CD4, further expanded in vitro by IL-2, and then fixed by glutaraldehyde.
Each vaccine portion will consist of 10,000 such cells suspended in saline and given subcutaneously every three months during the first year of the trial.
The outcome measures will be CD4 levels, specific immunity to HIV antigens, immune activation profile and HIV plasma viral loads, determined sequentially during the 24 months of the trial.
These outcome measures will be compared between the experimental and the control groups, to determine if this mode of treatment is effective in influencing CD4 levels as an additional mode of treatment during HIV infection.
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beer Sheba, Israel
- Soroka Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- CD4 cell counts -from 150 to 450/mm3 and stable for at least 12 months, and treatment with HAART for at least 6 months.
- Positive cell proliferation assay to CD4 molecule
- Low HIV viral load (<400 - 5000 copies/ml) for at least 12 months
- No change of antiretroviral treatment for at least 6 months
- Signed informed consent
Exclusion Criteria:
- Concomitant immunosuppressive or antineoplastic treatment as well as chronic systemic glucocorticoid therapy.
- Pregnancy and women without any efficacious contraception.
- Clinically relevant liver disease (AST and/or ALT >2,5x upper limit of normal range, or total bilirubin > 3,5 mg/dl).
- Serum creatinine >1,8mg/dl or creatinine clearance <30ml/min.
- Patients who cannot fully understand the treatment protocol or are unable to sign the informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vaccination
One arm of open label T cell vaccination in which all participants will receive the T cell vaccine
|
Approximately 10-20 million glutaraldehyde fixed CD4 responsive autologous T cells in 1-2 ml, per vaccine injection.
Approximately 10-20 million autologous CD4 reactive T cells per each vaccine injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
CD4 T cell levels
Time Frame: one year follow up
|
one year follow up
|
HIV plasma viral load
Time Frame: one year follow up
|
one year follow up
|
Clinical HIV infection
Time Frame: one year follow up
|
one year follow up
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
HIV specific immune responses
Time Frame: One year follow up
|
One year follow up
|
CD4 specific responses
Time Frame: One year follow up
|
One year follow up
|
Immune profile
Time Frame: One year follow up
|
One year follow up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Klaris Riesenberg, M.D., Soroka U Medical Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Abulafia-Lapid R, Bentwich Z, Keren-Zur Y, Cohen IR, Atlan H. T-cell vaccination against anti-CD4 autoimmunity in HIV-1 infected patients. J Clin Virol. 2004 Dec;31 Suppl 1:S48-54. doi: 10.1016/j.jcv.2004.09.017.
- Abulafia-Lapid R, Mayan S, Bentwich Z, Keren-Zur Y, Avbramovitz Y, Cohen IR, Atlan H. T-cell vaccination against anti-CD4 autoimmunity in HIV-1 subtypes B and C-infected patients--an extended open trial. Vaccine. 2005 Mar 18;23(17-18):2149-53. doi: 10.1016/j.vaccine.2005.01.054.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2006
Primary Completion (Actual)
November 1, 2008
Study Completion (Actual)
November 1, 2008
Study Registration Dates
First Submitted
December 3, 2006
First Submitted That Met QC Criteria
December 3, 2006
First Posted (Estimate)
December 5, 2006
Study Record Updates
Last Update Posted (Estimate)
December 2, 2009
Last Update Submitted That Met QC Criteria
December 1, 2009
Last Verified
November 1, 2006
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Blood-Borne Infections
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Disease Attributes
- Slow Virus Diseases
- HIV Infections
- Infections
- Communicable Diseases
- Acquired Immunodeficiency Syndrome
Other Study ID Numbers
- sor444006ctil
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on T cell vaccination
-
Sheba Medical CenterUnknown
-
Sheba Medical CenterUnknownMultiple SclerosisIsrael
-
University of SydneyUnknownComplication of TransplantAustralia
-
Hadassah Medical OrganizationCompleted
-
University Hospital, AntwerpCompletedRenal Cell Carcinoma | Glioblastoma | Malignant Mesothelioma | Colorectal Tumors | Breast Cancers | SarcomasBelgium
-
University Hospital, AntwerpUnknownAcute Myeloid Leukemia | Multiple Myeloma | Chronic Myeloid LeukemiaBelgium
-
University of Erlangen-Nürnberg Medical SchoolGerman Research Foundation; Charite University, Berlin, Germany; Ludwig-Maximilians... and other collaboratorsCompletedPatients Undergoing Allogeneic Stem Cell TransplantationGermany
-
Baylor College of MedicineUniversity of Texas, Southwestern Medical Center at DallasCompletedLeukemia | CancerUnited States
-
Southern Cancer CenterUniversity of South Alabama; Quantum Immunologics, Inc.UnknownMetastatic Breast CancerUnited States
-
Baylor Research InstituteMary Crowley Medical Research Center; ODC TherapyCompletedMelanoma | Neoplasm MetastasisUnited States